EA202092248A1 - Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими - Google Patents

Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими

Info

Publication number
EA202092248A1
EA202092248A1 EA202092248A EA202092248A EA202092248A1 EA 202092248 A1 EA202092248 A1 EA 202092248A1 EA 202092248 A EA202092248 A EA 202092248A EA 202092248 A EA202092248 A EA 202092248A EA 202092248 A1 EA202092248 A1 EA 202092248A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aminoisoindoline
dione
methods
compositions
treatment
Prior art date
Application number
EA202092248A
Other languages
English (en)
Inventor
Мэттью Д. Александер
Сорайя Каррансио
Мэттью Д. Корреа
Вирджиния Хитер Шэррон Грант
Джошуа Хансен
Рой Л. Харрис
Дехуа Хуан
Тимоти С. Керхер
Антония Лопес-Хирона
Марк А. Нэйджи
Вероник Плантевин-Кренитски
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA202092248A1 publication Critical patent/EA202092248A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

В данном документе предложены соединения 4-аминоизоиндолин-1,3-диона, имеющие следующую формулу:где R, кольцо A и n являются такими, как определено в данном документе, композиции, содержащие эффективное количество соединения 4-аминоизоиндолин-1,3-диона, и способы лечения или предупреждения расстройств.
EA202092248A 2018-04-23 2019-04-22 Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими EA202092248A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661525P 2018-04-23 2018-04-23
PCT/US2019/028471 WO2019209692A1 (en) 2018-04-23 2019-04-22 Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Publications (1)

Publication Number Publication Date
EA202092248A1 true EA202092248A1 (ru) 2021-02-04

Family

ID=66641467

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092248A EA202092248A1 (ru) 2018-04-23 2019-04-22 Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими

Country Status (28)

Country Link
US (2) US11358952B2 (ru)
EP (2) EP4272737A3 (ru)
JP (1) JP7458324B2 (ru)
KR (1) KR20210003103A (ru)
CN (2) CN113214220B (ru)
AR (1) AR114803A1 (ru)
AU (2) AU2019261273B2 (ru)
BR (1) BR112020021552B1 (ru)
CA (1) CA3096404A1 (ru)
CL (1) CL2020002696A1 (ru)
CO (1) CO2020012824A2 (ru)
DK (1) DK3784663T3 (ru)
EA (1) EA202092248A1 (ru)
ES (1) ES2959622T3 (ru)
FI (1) FI3784663T3 (ru)
HR (1) HRP20231199T1 (ru)
HU (1) HUE064340T2 (ru)
IL (1) IL277435A (ru)
LT (1) LT3784663T (ru)
MX (2) MX2020011183A (ru)
PE (1) PE20211375A1 (ru)
PL (1) PL3784663T3 (ru)
PT (1) PT3784663T (ru)
RS (1) RS64663B1 (ru)
SG (1) SG11202009237XA (ru)
SI (1) SI3784663T1 (ru)
TW (1) TWI814815B (ru)
WO (1) WO2019209692A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
RS64936B1 (sr) 2019-10-21 2024-01-31 Celgene Corp Metodi lečenja hematoloških maligniteta korišćenjem 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benz il)amino-)izoindolin 1,3-diona
EP4048668A4 (en) * 2019-10-21 2024-03-13 Celgene Corp METHODS OF TREATING HEMATOLOGICAL CANCER AND USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL) BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
CA3154956A1 (en) * 2019-10-21 2021-04-29 Lianfeng Huang Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
EP4048279A1 (en) * 2019-10-21 2022-08-31 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
CN115671295A (zh) * 2019-10-21 2023-02-03 新基公司 包含化合物的药物组合物及其使用方法
EP4048260A1 (en) * 2019-10-21 2022-08-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
WO2021147889A1 (zh) * 2020-01-20 2021-07-29 康朴生物医药技术（上海）有限公司 一种异吲哚啉衍生物、其药物组合物及应用
TW202241872A (zh) * 2021-01-05 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
IL307257A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
US20220362255A1 (en) * 2021-04-21 2022-11-17 Celgene Corporation Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN117279640A (zh) 2021-04-21 2023-12-22 新基公司 使用组合疗法治疗b细胞淋巴瘤的方法
EP4359380A1 (en) 2021-06-21 2024-05-01 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
WO2023025136A1 (zh) * 2021-08-27 2023-03-02 杭州格博生物医药有限公司 异吲哚啉酮化合物及其用途
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
CN117088864A (zh) * 2022-05-13 2023-11-21 广州智药生物科技有限公司 一种苯并[d]异恶唑类化合物及其应用
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ES2521672T3 (es) 2002-05-17 2014-11-13 Celgene Corporation Formulaciones farmacéuticas para el tratamiento del cáncer
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CN100398534C (zh) 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005282728A1 (en) 2004-09-03 2006-03-16 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
AU2005304420A1 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
SI2380887T1 (sl) 2005-06-30 2013-12-31 Celgene Corporation Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
AU2006332680A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007136640A2 (en) 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
ES2426350T3 (es) 2006-08-30 2013-10-22 Celgene Corporation Compuestos de isoindolina sustituidos en 5
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP5567339B2 (ja) * 2006-09-15 2014-08-06 セルジーン コーポレイション Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法
NZ579890A (en) 2007-03-20 2012-05-25 Celgene Corp 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
CN101909609A (zh) 2007-11-08 2010-12-08 细胞基因公司 免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途
KR20170007531A (ko) 2008-10-29 2017-01-18 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
PT3202461T (pt) * 2010-02-11 2019-03-19 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CN105061438B (zh) * 2010-06-23 2017-07-04 韩美科学株式会社 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物
WO2012112919A1 (en) 2011-02-17 2012-08-23 Rhode Island Hostpital Stromal derived factor inhibition and cxcr4 blockade
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
RU2695521C9 (ru) * 2014-10-30 2019-08-19 Канпу Биофармасьютикалс, Лтд. Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
DK3357513T3 (da) 2015-09-29 2023-11-27 Kangpu Biopharmaceuticals Inc Farmaceutisk sammensætning og anvendelse deraf
KR102331013B1 (ko) 2016-01-14 2021-11-26 강푸 바이오파마슈티칼즈 리미티드 퀴나졸리논 유도체, 이의 제조방법, 약학 조성물 및 적용
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
RU2021102253A (ru) 2016-04-06 2021-03-03 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
AU2017281903B2 (en) 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US10702504B2 (en) 2016-06-23 2020-07-07 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
RS64208B1 (sr) 2016-10-11 2023-06-30 Arvinas Operations Inc Jedinjenja i metode za ciljanu degradaciju androgenog receptora
SG11201903483VA (en) 2016-10-28 2019-05-30 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
EP3535254A4 (en) 2016-11-01 2020-06-24 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") COMPOUNDS FOR THE DEGRADATION OF MALT1
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
CN110291087A (zh) 2016-12-01 2019-09-27 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
CN107056772A (zh) 2017-01-23 2017-08-18 中国药科大学 基于cereblon配体诱导BET降解的双功能分子及其制备和应用
JP7266526B6 (ja) 2017-01-26 2024-02-15 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
CN110612294B (zh) 2017-01-31 2024-01-16 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
CN110248662B (zh) 2017-02-13 2022-08-16 康朴生物医药技术（上海）有限公司 一种治疗前列腺癌的组合、药物组合物及治疗方法
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
KR102656934B1 (ko) * 2017-07-10 2024-04-16 셀진 코포레이션 항증식성 화합물 및 이의 사용 방법
EP4310496A2 (en) 2017-07-12 2024-01-24 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
CN107698575A (zh) 2017-09-26 2018-02-16 中国药科大学 cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
CN108715585A (zh) 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN108794453A (zh) 2018-07-05 2018-11-13 清华大学 一种靶向降解fak蛋白的化合物及其应用

Also Published As

Publication number Publication date
US20220306611A1 (en) 2022-09-29
US20190322647A1 (en) 2019-10-24
BR112020021552A2 (pt) 2021-01-19
DK3784663T3 (da) 2023-10-16
TW202003492A (zh) 2020-01-16
CO2020012824A2 (es) 2021-01-18
HRP20231199T1 (hr) 2024-01-19
PL3784663T3 (pl) 2023-12-27
US11945804B2 (en) 2024-04-02
RS64663B1 (sr) 2023-11-30
TWI814815B (zh) 2023-09-11
SI3784663T1 (sl) 2023-11-30
MX2020011183A (es) 2020-11-12
AU2019261273A1 (en) 2020-10-22
US11358952B2 (en) 2022-06-14
CN111989322A (zh) 2020-11-24
EP4272737A2 (en) 2023-11-08
CN111989322B (zh) 2024-04-02
ES2959622T3 (es) 2024-02-27
CL2020002696A1 (es) 2021-02-19
CA3096404A1 (en) 2019-10-31
PT3784663T (pt) 2023-10-10
KR20210003103A (ko) 2021-01-11
WO2019209692A1 (en) 2019-10-31
MX2023005160A (es) 2023-05-29
SG11202009237XA (en) 2020-10-29
BR112020021552B1 (pt) 2023-04-11
AU2019261273B2 (en) 2023-03-09
JP2021523885A (ja) 2021-09-09
CN113214220A (zh) 2021-08-06
PE20211375A1 (es) 2021-07-27
JP7458324B2 (ja) 2024-03-29
EP4272737A3 (en) 2024-01-17
EP3784663B1 (en) 2023-07-12
IL277435A (en) 2020-11-30
HUE064340T2 (hu) 2024-03-28
AU2023203504A1 (en) 2023-06-29
EP3784663A1 (en) 2021-03-03
FI3784663T3 (fi) 2023-10-06
AR114803A1 (es) 2020-10-14
CN113214220B (zh) 2024-04-02
LT3784663T (lt) 2023-10-25

Similar Documents

Publication Publication Date Title
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
PH12021500014A1 (en) Fused ring compounds
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
EA201790992A1 (ru) Иммунорегуляторные агенты
GEP20237506B (en) Pcsk9 antagonist compounds
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA202191519A1 (ru) Модуляторы trex1
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
EA202092086A1 (ru) Ингибиторы аргиназы
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201990400A1 (ru) Соединения и композиции и их применение
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA201892815A1 (ru) Новые антибактериальные соединения
EA201792287A1 (ru) Способы лечения рака
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202190070A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA202190576A1 (ru) Полиморфные соединения и их применение
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting